Payment overview · 2025
General Payments
$1,293.17
21 reported records · 12 companies
Healthcare provider profile · identity verified
Michael C Maxwell, M.D.
Allopathic & Osteopathic Physicians|Thoracic Surgery (Cardiothoracic Vascular Surgery) · BOZEMAN, MT · NPI 1114926300
Verified facts
What the public records show
CMS Open Payments records show Michael C Maxwell, M.D. received $1,293.17 in general payments during 2025 across 21 reported records.
W. L. Gore & Associates, Inc. accounted for 47.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $609.18 | 47.1% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$254.54 | 19.7% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $163.63 | 12.7% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $81.42 | 6.3% | 3 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $27.13 | 2.1% | 1 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $26.92 | 2.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $26.02 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.14 | 1.7% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $21.64 | 1.7% | 1 | 2025 |
| Merit Medical Systems Inc | Unresolved — no canonical attribution shown | $21.17 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.14 | 1.6% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $18.24 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,293.17 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $382.33 | 4 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $204.75 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $163.63 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $160.78 | 1 | 2025 |
Source payment records
|
|||||
| AVALUS Normalized: avalus |
Device | Medtronic, Inc. | $93.76 | 1 | 2025 |
Source payment records
|
|||||
| PREVELEAK Normalized: preveleak |
Device | Baxter Healthcare | $27.13 | 1 | 2025 |
Source payment records
|
|||||
| COOK Normalized: cook |
Device | Cook Medical LLC | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| Mechanical Tools Normalized: mechanical tools |
Device | Philips North America LLC | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| EPIC Normalized: epic |
Device | Abbott Laboratories | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Becton, Dickinson and Company | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| Safeguard Focus Normalized: safeguard focus |
Device | Merit Medical Systems Inc | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| CODMAN CERTAS Normalized: codman certas |
Device | Integra LifeSciences Corporation | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| CODMAN HAKIM Normalized: codman hakim |
Device | Integra LifeSciences Corporation | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| CUSA CLARITY Normalized: cusa clarity |
Device | Integra LifeSciences Corporation | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| DuraSeal Exact Spinal Sealant System Normalized: duraseal exact spinal sealant system |
Device | Integra LifeSciences Corporation | $18.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,293.17 · 21 records | W. L. Gore & Associates, Inc. | AVALUS, CODMAN CERTAS, CODMAN HAKIM, COOK, COREVALVE EVOLUT R, CUSA CLARITY, DuraSeal Exact Spinal Sealant System, EPIC, EXCLUDER Conformable AAA Endoprosthesis with Active Control, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE VIABAHN VBX Balloon Expandable Endo, Mechanical Tools, PAXLOVID, PREVELEAK, RotarexS 6 F x 135 cm, SAPIEN 3 Ultra RESILIA, Safeguard Focus | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error